Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
Clinical trial NCT04318080 · COMPLETED
Trial details
- NCT number
- NCT04318080
- Sponsor
- BeiGene
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-20
- Primary completion
- 2022-12-12
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.